Research Papers:

An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells

Sujing Yuan, Xianlong Fang, Aimin Ni, Xin-Yuan Liu _ and Liang Chu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:60491-60502. https://doi.org/10.18632/oncotarget.11134

Metrics: PDF 2074 views  |   HTML 3068 views  |   ?  


Sujing Yuan1, Xianlong Fang1, Yanni Xu2, Aimin Ni1, Xin-Yuan Liu1, Liang Chu1,3

1State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, P. R. China

2College of Life Sciences, Northwest Agriculture and Forestry University, Yangling 712100, P. R. China

3Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou 221002, P. R. China

Correspondence to:

Xin-Yuan Liu, email: [email protected]

Liang Chu, email: [email protected]

Keywords: oncolytic adenovirus, HAb18, CD147, interleukin 24, hepatocellular carcinoma

Received: January 18, 2016     Accepted: July 26, 2016     Published: August 09, 2016


Hepatocellular carcinoma (HCC) is characterized by alterations in multiple genes. High expression of CD147 on the surface of HCC cells promotes proliferation. The monoclonal antibody HAb18 recognizes CD147. We constructed an oncolytic adenoviral vector to express HAb18 (ZD55-HAb18) in HCC cells. Interleukin 24 (IL24) was co-expressed through the use of an F2A linker. ZD55-HAb18-IL24 decreased HCC cell viability to a greater degree than either ZD55-HAb18 or ZD55-IL24 alone. ZD55-HAb18-IL24 also induced apoptosis and autophagy in PLC/PRF/5 HCC cells. Intratumoral injection of ZD55-HAb18-IL24 repressed tumor growth in a PLC/PRF/5 xenograft model. Our results suggest that antibody-antitumor gene conjugation elicited a stronger antitumor effect than the antibody alone, and that this strategy could broaden the applications of antibody-based therapies in HCC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11134